BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BMY - US1101221083 - Common Stock
48.18 EUR
+9.78 (+25.47%)
Taking everything into account, 1BMY scores 6 out of 10 in our fundamental rating. 1BMY was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on 1BMY. 1BMY also has an excellent dividend rating. These ratings would make 1BMY suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
- 1BMY had positive earnings in the past year.
- In the past year 1BMY had a positive cash flow from operations.
- In multiple years 1BMY reported negative net income over the last 5 years.
- 1BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- 1BMY has a Return On Assets (6.23%) which is comparable to the rest of the industry.
- With a decent Return On Equity value of 32.55%, 1BMY is doing good in the industry, outperforming 80.00% of the companies in the same industry.
- The Return On Invested Capital of 1BMY (17.49%) is better than 81.82% of its industry peers.
- 1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is below the industry average of 14.02%.
- The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(17.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.49% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
- With a Profit Margin value of 12.57%, 1BMY perfoms like the industry average, outperforming 52.73% of the companies in the same industry.
- 1BMY has a Operating Margin of 33.51%. This is amongst the best in the industry. 1BMY outperforms 81.82% of its industry peers.
- 1BMY's Operating Margin has declined in the last couple of years.
- 1BMY has a Gross Margin of 73.15%. This is comparable to the rest of the industry: 1BMY outperforms 60.00% of its industry peers.
- In the last couple of years the Gross Margin of 1BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
- 1BMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for 1BMY has been reduced compared to 1 year ago.
- 1BMY has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, 1BMY has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.10 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
- 1BMY has a worse Altman-Z score (2.10) than 60.00% of its industry peers.
- 1BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as 1BMY would need 3.20 years to pay back of all of its debts.
- 1BMY has a Debt to FCF ratio of 3.20. This is in the better half of the industry: 1BMY outperforms 61.82% of its industry peers.
- A Debt/Equity ratio of 2.41 is on the high side and indicates that 1BMY has dependencies on debt financing.
- With a Debt to Equity ratio value of 2.41, 1BMY is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.1 |
ROIC/WACC2.11
WACC8.3%
2.3 Liquidity
- A Current Ratio of 1.27 indicates that 1BMY should not have too much problems paying its short term obligations.
- 1BMY has a Current ratio of 1.27. This is in the lower half of the industry: 1BMY underperforms 65.45% of its industry peers.
- 1BMY has a Quick Ratio of 1.17. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
- 1BMY has a Quick ratio of 1.17. This is in the better half of the industry: 1BMY outperforms 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 460.68% over the past year.
- 1BMY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
- Looking at the last year, 1BMY shows a small growth in Revenue. The Revenue has grown by 1.26% in the last year.
- The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
- Based on estimates for the next years, 1BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 35.26% on average per year.
- 1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.97% yearly.
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 8.56, the valuation of 1BMY can be described as very reasonable.
- 94.55% of the companies in the same industry are more expensive than 1BMY, based on the Price/Earnings ratio.
- 1BMY is valuated cheaply when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- 1BMY is valuated reasonably with a Price/Forward Earnings ratio of 9.21.
- Based on the Price/Forward Earnings ratio, 1BMY is valued cheaper than 90.91% of the companies in the same industry.
- 1BMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.56 | ||
| Fwd PE | 9.21 |
4.2 Price Multiples
- 1BMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMY is cheaper than 92.73% of the companies in the same industry.
- 1BMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1BMY is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.46 | ||
| EV/EBITDA | 5.97 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as 1BMY's earnings are expected to grow with 73.98% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.22%
EPS Next 3Y73.98%
5. Dividend
5.1 Amount
- 1BMY has a Yearly Dividend Yield of 4.77%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.72, 1BMY pays a better dividend. On top of this 1BMY pays more dividend than 90.91% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.89, 1BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
5.2 History
- On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 82.81% of the earnings are spent on dividend by 1BMY. This is not a sustainable payout ratio.
- 1BMY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
BIT:1BMY (1/15/2026, 7:00:00 PM)
48.18
+9.78 (+25.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-05 2026-02-05/amc
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap98.08B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target45.28 (-6.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
Yearly Dividend2.07
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.04%
PT rev (3m)-2%
EPS NQ rev (1m)5.31%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)1.98%
Revenue NQ rev (3m)2.19%
Revenue NY rev (1m)1.32%
Revenue NY rev (3m)1.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.56 | ||
| Fwd PE | 9.21 | ||
| P/S | 2.38 | ||
| P/FCF | 7.46 | ||
| P/OCF | 6.87 | ||
| P/B | 6.16 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.97 |
EPS(TTM)5.63
EY11.69%
EPS(NY)5.23
Fwd EY10.86%
FCF(TTM)6.45
FCFY13.4%
OCF(TTM)7.01
OCFY14.55%
SpS20.26
BVpS7.83
TBVpS-9.98
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.49% | ||
| ROICexc | 22.99% | ||
| ROICexgc | 117.18% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.1 |
F-Score6
WACC8.3%
ROIC/WACC2.11
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year262.1%
EBIT Next 3Y50.55%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?
ChartMill assigns a fundamental rating of 6 / 10 to 1BMY.MI.
Can you provide the valuation status for BRISTOL-MYERS SQUIBB CO?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.
Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.
Can you provide the financial health for 1BMY stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 5 / 10.
Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?
The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 8 / 10 and the dividend payout ratio is 82.81%.